NDAORALTABLET
Approved
Mar 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
GLYNASE (glyburide) by Pfizer is clinical pharmacology actions glyburide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. First approved in 1992.
Drug data last refreshed 14h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GLYNASE (glyburide) is an oral sulfonylurea small molecule that lowers blood glucose by stimulating insulin release from pancreatic beta cells in Type 2 diabetes patients. It is used as monotherapy or in combination with metformin to improve glucose tolerance through both pancreatic and extrapancreatic mechanisms. The drug maintains a 24-hour glucose-lowering effect despite declining insulin secretory response with chronic administration.
$17KPart D
LOE ApproachingDeclining
This mature product approaching loss of exclusivity signals a contracting brand team with focus on managed decline rather than growth investment.
Mechanism of Action
CLINICAL PHARMACOLOGY Actions Glyburide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which glyburide lowers blood glucose during long-term administration…
Worked on GLYNASE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.